migraine headache. Migraine
Conditions
Interventions
Intervention 1: Intervention group: intervention group will receive 1 capsule which contains 2000 of vitamin D every day for 12 weeks. Intervention 2: Control group: placebo group will receive 1 caps
Sponsors
Tehran University of Medical Sciences
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: having BMI between 18.5-30 kg/m2 Migraine diagnosis according to The International Classification of Headache Disorders 3rd edition having 3-15 migraine headache attacks in last 3 months suffering from migraine for at least 6 months prior to study
Exclusion criteria
Exclusion criteria: unwillingness to participate in the study daily consumption of NSAIDs in 3 months prior to study taking vitamin D supplements in 3 months prior to study taking magnesium, calcium, zinc, vitamin B groups and vitamin C supplements during the study period taking anti-epileptic drugs such as topiramate, sodium valproate and carbamazepine taking thiazide diuretics, Glucocorticoid, statins and orlistat taking anti-psychotic drugs menopause pregnancy and lactation suffering from gastrointestinal disorders (IBD, IBS,...), liver and kidney disorders, cancer, Sarcoidosis, rickets, and osteomalacia based on physician diagnosis and/or past medical history
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Migraine attack frequency per month. Timepoint: baseline-end of study. Method of measurement: headache diary.;Attack severity. Timepoint: baseline-end of study. Method of measurement: headache diary-visual analogue scale.;Headache attack duration (min per month). Timepoint: baseline-end of study. Method of measurement: headache diary-visual analogue scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum 25 (OH) D3. Timepoint: baseline- end of study. Method of measurement: laboratory test.;Serum vitamin D receptor. Timepoint: baseline- end of study. Method of measurement: laboratory test.;Determining inflammatory status (including serum levels of iNOS, IL 6, Cox 2, CGRP, and IL10 ). Timepoint: baseline- end of study. Method of measurement: laboratory test.;Determining Treg/th17 balance (including serum levels of TGF b and IL-17). Timepoint: baseline- end of study. Method of measurement: laboratory test.;Serum prolactin levels. Timepoint: baseline- end of study. Method of measurement: laboratory test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Maryam Mahmoudi
Tehran University of Medical Sciences
Outcome results
None listed